XuanwuH 2
10
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
Role: lead
Early Diagnosis of SCD Based on Radiogenomics
Role: lead
Intervention of Intestinal Microorganism in Mild Cognitive Impairment
Role: lead
Transcranial Photobiomodulation Intervention for Healthy Older Adults
Role: lead
Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD
Role: lead
Neurofeedback Intervention for Preclinical Alzheimer's Disease
Role: lead
Non-pharmacological Intervention for Preclinical Alzheimer's Disease
Role: lead
Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology
Role: lead
Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion
Role: lead
Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase
Role: lead
All 10 trials loaded